نتایج جستجو برای: آنتیبادی مونوکلونال trastuzumab
تعداد نتایج: 9324 فیلتر نتایج به سال:
Resistance to the anti-HER2 monoclonal antibody trastuzumab is a major problem in the treatment of HER2-overexpressing metastatic breast cancer. Growth differentiation factor 15 (GDF15), which is structurally similar to TGF beta, has been reported to stimulate phosphorylation of HER2. We tested the hypothesis that GDF15-mediated phosphorylation of HER2 reduces the sensitivity of HER2-overexpres...
Breast cancer radioimmunoscintigraphy targeting HER2/neu expression is a growing fieldof work in nuclear medicine research. In this study, trastuzumab was successively labeledwith [67Ga] GaCl3 after conjugation with DOTA-NHS-ester.The conjugates were purified by molecular filtration, the average number ofDOTA conjugated per mAb was calculated and total concentration was determined byspectrophot...
Trastuzumab has been used for the treatment of HER2-overexpressing breast cancer for more than a decade, but the mechanisms of action for the therapy are still being actively investigated. Ab-dependent cell-mediated cytotoxicity mediated by NK cells is well recognized as one of the key mechanisms of action for trastuzumab, but trastuzumab-mediated Ab-dependent cellular phagocytosis (ADCP) has n...
Following the pivotal clinical trials of trastuzumab (Herceptin), further phase II and III studies have been initiated. Preliminary results from a phase II, dose-response study of single-agent trastuzumab in 113 HER2-positive metastatic breast cancer patients without prior chemotherapy for stage IV disease have shown that the overall response rate was 23% (six complete responses and 20 partial ...
مقدمه: سرطان یکی از مهمترین چالش‌های بهداشتی قرن اخیر و آینده میباشد. طراحی داروهای ضدسرطان هدفمند، مبتنی بر آنتی‌بادی‌های مونوکلونال، نیازمند درک مکانیسم تعامل آنتیبادی–پروتئین در سطح باقی‌مانده‌ها است. اولین گام برای تولید آنتی‌بادی‌های مونوکلونال، پیش‌بینی ساختار آن‌ها میباشد. روش: در این مقاله، مهمترین تحقیقات منتشر شده در پایگاه‌های اطلاعاتی PubMed، ScienceDirect، Springer و IEEE، برای...
We sought to describe patterns of treatment and clinical outcome in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy. One hundred eighty-four consecutive HER2-positive advanced breast cancer patients received trastuzumab-based therapy between September 1999 and September 2004. Patients were followed up until death or May 2005. For patients progressing ...
Trastuzumab prolongs survival in HER2 positive breast cancer patients. However, resistance remains a challenge. We have previously shown that ADAM17 plays a key role in maintaining HER2 phosphorylation during trastuzumab treatment. Beside ADAM17, ADAM10 is the other well characterized ADAM protease responsible for HER ligand shedding. Therefore, we studied the role of ADAM10 in relation to tras...
BACKGROUND The aim of this retrospective analysis was to evaluate the impact of trastuzumab-based regimens on the survival of patients with HER2-overexpressing metastatic breast cancer (MBC). The study specifically focussed on the influence of the continuation of trastuzumab-based treatment despite tumor progression on survival. PATIENTS AND METHODS Patients with HER2 overexpressing MBC were ...
Trastuzumab (Herceptin®) is a humanized monoclonal antibody designed to bind and inhibit the function of the human epidermal growth factor receptor 2 (HER2)/erbB2 receptor. Trastuzumab has demonstrated clinical activity in several types of HER2-overexpressing epithelial tumors, such as breast and metastatic gastric or gastroesophageal junction can...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید